Investor’s Alert on Worth Watching Stocks: U.S. Bancorp (NYSE:USB), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

On Tuesday, Shares of U.S. Bancorp (NYSE:USB), subtract -0.51% and shut at $49.03 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $48.76 and $49.57. Elavon, a leading global payments provider and partner of U.S. Bancorp (USB), and Systems Innovators (SI), a leading enterprise revenue administration and centralized cashiering provider, have teamed up with government agencies to deploy a payment system that assists protect citizens’ information, assists prevent fraud and provides industry-compliant EMV technology.

Jeff Sumner, executive vice president of System Innovators, said, “We are focused on delivering the most trusted central cashiering and revenue administration systems for U.S. governments and utilities. Partnering with Elavon on this certified EMV product designed specifically for those entities, assists them accept EMV and chip card payments, while mitigating the risk of credit card fraud.”

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), subtract -2.50% and shut at $37.83 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $37.56 and $38.69. The association’s commercial center capitalization is $38.60 Billion with the general uncommon loads of 1.01 billion. Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) recently declared it has obtained approval from the European Commission for an indication extension of Trisenox® (arsenic trioxide). This marks an important advancement in treatment for Acute Promyelocytic Leukemia (APL) patients in Europe, as it is the first time that a form of acute leukemia can be effectively treated with a regimen that is entirely chemotherapy-free. APL is a rare and aggressive type of acute leukemia that can kill within hours or days if left untreated2. Trisenox®, in combination with retinoic acid, has shown a 99% overall survival rate with almost no relapses after more than four years (50 months) of median follow-up1.

“Teva is committed to providing wider access to high-quality medicines to ensure more people can benefit from the treatments they need. We’re very happy by this decision of the European Commission, and we look forward to offering a chemotherapy-free treatment option for all newly diagnosed APL patients,” said Rob Koremans, MD, President & CEO, Teva Global Specialty Medicines.

Leave a Reply

Your email address will not be published. Required fields are marked *